Stern DF, Heffernan PA, Weinberg RA. P185, a product of the neu proto-oncogene, is a receptorlike protein associated with tyrosine kinase activity. Mol Cell Biol. 1986;6(5):1729–40. https://doi.org/10.1128/mcb.6.5.1729-1740.1986.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Schechter AL, Stern DF, Vaidyanathan L, Decker SJ, Drebin JA, Greene MI, et al. The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen. Nature. 1984;312(5994):513–6. https://doi.org/10.1038/312513a0.

Article  CAS  PubMed  Google Scholar 

Valenza C, Guidi L, Battaiotto E, Trapani D, Sartore Bianchi A, Siena S, et al. Targeting HER2 heterogeneity in breast and gastrointestinal cancers. Trends Cancer. 2024;10(2):113–23. https://doi.org/10.1016/j.trecan.2023.11.001.

Article  CAS  PubMed  Google Scholar 

Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344(11):783–92. https://doi.org/10.1056/NEJM200103153441101.

Article  CAS  PubMed  Google Scholar 

Romond EH, Perez EA, Bryant J, Suman VJ, Geyer JCE, Davidson NE, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353(16):1673–84. https://doi.org/10.1056/NEJMoa052122.

Article  CAS  PubMed  Google Scholar 

Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376(9742):687–97. https://doi.org/10.1016/S0140-6736(10)61121-X.

Article  CAS  PubMed  Google Scholar 

Shitara K, Bang YJ, Iwasa S, Sugimoto N, Ryu MH, Sakai D, et al. Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer. N Engl J Med. 2020;382(25):2419–30. https://doi.org/10.1056/NEJMoa2004413.

Article  CAS  PubMed  Google Scholar 

Janjigian YY, Kawazoe A, Bai Y, Xu J, Lonardi S, Metges JP, et al. Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial. Lancet. 2023;402(10418):2197–208. https://doi.org/10.1016/S0140-6736(23)02033-0.

Article  CAS  PubMed  Google Scholar 

Wakatsuki T, Yamamoto N, Sano T, Chin K, Kawachi H, Takahari D, et al. Clinical impact of intratumoral HER2 heterogeneity on trastuzumab efficacy in patients with HER2-positive gastric cancer. J Gastroenterol. 2018;53(11):1186–95. https://doi.org/10.1007/s00535-018-1464-0.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yagi S, Wakatsuki T, Yamamoto N, Chin K, Takahari D, Ogura M, et al. Clinical significance of intratumoral HER2 heterogeneity on trastuzumab efficacy using endoscopic biopsy specimens in patients with advanced HER2 positive gastric cancer. Gastric Cancer. 2019;22(3):518–25. https://doi.org/10.1007/s10120-018-0887-x.

Article  CAS  PubMed  Google Scholar 

Marshall S, Wakatsuki T, Takahari D, Matsushima T, Ishizuka N, Nakayama I, et al. Prognostic factors in patients with advanced HER2-positive gastric cancer treated with trastuzumab-based chemotherapy: a cohort study. J Gastrointest Cancer. 2023;54(2):475–84. https://doi.org/10.1007/s12029-022-00815-1.

Article  CAS  PubMed  Google Scholar 

Shimozaki K, Shinozaki E, Yamamoto N, Imamura Y, Osumi H, Nakayama I, et al. KRAS mutation as a predictor of insufficient trastuzumab efficacy and poor prognosis in HER2-positive advanced gastric cancer. J Cancer Res Clin Oncol. 2023;149(3):1273–83. https://doi.org/10.1007/s00432-022-03966-7.

Article  CAS  PubMed  Google Scholar 

Cancer Genome Atlas Research N. Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014;513(7517):202–9. https://doi.org/10.1038/nature13480.

Article  CAS  Google Scholar 

Ali SM, Sanford EM, Klempner SJ, Rubinson DA, Wang K, Palma NA, et al. Prospective comprehensive genomic profiling of advanced gastric carcinoma cases reveals frequent clinically relevant genomic alterations and new routes for targeted therapies. Oncologist. 2015;20(5):499–507. https://doi.org/10.1634/theoncologist.2014-0378.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kuboki Y, Yamashita S, Niwa T, Ushijima T, Nagatsuma A, Kuwata T, et al. Comprehensive analyses using next-generation sequencing and immunohistochemistry enable precise treatment in advanced gastric cancer. Ann Oncol. 2016;27(1):127–33. https://doi.org/10.1093/annonc/mdv508.

Article  CAS  PubMed  Google Scholar 

Yu P, Wang Y, Yu Y, Wang A, Huang L, Zhang Y, et al. Deep targeted sequencing and its potential implication for cancer therapy in Chinese patients with gastric adenocarcinoma. Oncologist. 2021;26(5):e756–68. https://doi.org/10.1002/onco.13695.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hino K, Nishina T, Kajiwara T, Bando H, Nakamura M, Kadowaki S, et al. Association of ERBB2 copy number and gene coalterations with trastuzumab efficacy and resistance in human epidermal growth factor receptor 2-positive esophagogastric and gastric cancer. JCO Precis Oncol. 2022;6:e2200135. https://doi.org/10.1200/PO.22.00135.

Article  PubMed  PubMed Central  Google Scholar 

Janjigian YY, Sanchez-Vega F, Jonsson P, Chatila WK, Hechtman JF, Ku GY, et al. Genetic predictors of response to systemic therapy in esophagogastric cancer. Cancer Discov. 2018;8(1):49–58. https://doi.org/10.1158/2159-8290.CD-17-0787.

Article  CAS  PubMed  Google Scholar 

Zhang L, Hamdani O, Gjoerup O, Cho-Phan C, Snider J, Castellanos E, et al. ERBB2 copy number as a quantitative biomarker for real-world outcomes to anti-human epidermal growth factor receptor 2 therapy in advanced gastroesophageal adenocarcinoma. JCO Precis Oncol. 2022;6:e2100330. https://doi.org/10.1200/PO.21.00330.

Article  PubMed  PubMed Central  Google Scholar 

Deng N, Goh LK, Wang H, Das K, Tao J, Tan IB, et al. A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets. Gut. 2012;61(5):673–84. https://doi.org/10.1136/gutjnl-2011-301839.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kim J, Fox C, Peng S, Pusung M, Pectasides E, Matthee E, et al. Preexisting oncogenic events impact trastuzumab sensitivity in ERBB2-amplified gastroesophageal adenocarcinoma. J Clin Investig. 2014;124(12):5145–58. https://doi.org/10.1172/JCI75200.

Article  PubMed  PubMed Central  Google Scholar 

Pietrantonio F, Fuca G, Morano F, Gloghini A, Corso S, Aprile G, et al. Biomarkers of primary resistance to trastuzumab in HER2-positive metastatic gastric cancer patients: the AMNESIA case-control study. Clin Cancer Res. 2018;24(5):1082–9. https://doi.org/10.1158/1078-0432.CCR-17-2781.

Article  CAS  PubMed  Google Scholar 

Diaz-Serrano A, Angulo B, Dominguez C, Pazo-Cid R, Salud A, Jimenez-Fonseca P, et al. Genomic profiling of HER2-positive gastric cancer: PI3K/Akt/mTOR pathway as predictor of outcomes in HER2-positive advanced gastric cancer treated with trastuzumab. Oncologist. 2018;23(9):1092–102. https://doi.org/10.1634/theoncologist.2017-0379.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Takahari D, Chin K, Ishizuka N, Takashima A, Minashi K, Kadowaki S, et al. Multicenter phase II study of trastuzumab with S-1 plus oxaliplatin for chemotherapy-naive, HER2-positive advanced gastric cancer. Gastric Cancer. 2019;22(6):1238–46. https://doi.org/10.1007/s10120-019-00973-5.

Article  CAS  PubMed  Google Scholar 

Wakatsuki T, Ishizuka N, Hironaka S, Minashi K, Kadowaki S, Goto M, et al. Exploratory analysis of serum HER2 extracellular domain for HER2 positive gastric cancer treated with SOX plus trastuzumab. Int J Clin Oncol. 2024;29(6):801–12. https://doi.org/10.1007/s10147-024-02509-z.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wakatsuki T, Irisawa A, Terashima M, Shibukawa G, Takagi T, Imamura H, et al. ATP assay-guided chemosensitivity testing for gemcitabine with biopsy specimens obtained from unresectable pancreatic cancer using endoscopic ultrasonography-guided fine-needle aspiration. Int J Clin Oncol. 2011;16(4):387–94.